Last updated: July 31, 2026
Niravam is the discontinued U.S. brand for alprazolam orally disintegrating tablets. The product was approved by the FDA for anxiety disorders and panic disorder, but no active Niravam-specific clinical development program or material branded-market opportunity is evident. Commercial demand has shifted to generic alprazolam products, primarily conventional tablets and orally disintegrating tablets.
What is Niravam and what was it approved to treat?
Niravam contains alprazolam, a benzodiazepine and central nervous system depressant. It was approved in the United States as an orally disintegrating tablet for:
- Anxiety disorders
- Short-term relief of symptoms of anxiety
- Anxiety associated with depression
- Panic disorder, with or without agoraphobia
The product was available in 0.25 mg, 0.5 mg, 1 mg and 2 mg strengths. Niravam was intended to dissolve in the mouth without water, but it contained the same active pharmaceutical ingredient as conventional alprazolam tablets.
| Attribute |
Niravam |
| Active ingredient |
Alprazolam |
| Drug class |
Benzodiazepine |
| Dosage form |
Orally disintegrating tablet |
| U.S. approval |
FDA-approved |
| Original sponsor |
Schwarz Pharma |
| Later corporate association |
UCB |
| Controlled-substance classification |
Schedule IV |
| Main indications |
Anxiety disorder and panic disorder |
| Current branded status |
Discontinued from commercial marketing |
| Main substitutes |
Generic alprazolam tablets and alprazolam ODT |
The FDA-approved label carries boxed warnings for abuse, misuse, addiction, physical dependence and withdrawal. Risks increase when alprazolam is used with opioids, alcohol or other central nervous system depressants.[1]
What is the FDA and Orange Book status of Niravam?
Niravam is not a current branded growth product. The FDA product record identifies the product as discontinued rather than withdrawn for safety or efficacy reasons. The discontinued status means that the brand no longer has a meaningful active commercial position in the U.S. market.
The product’s regulatory history is important because Niravam’s commercial value depended on a differentiated delivery format rather than a new molecular entity. Alprazolam itself is an established generic active ingredient with extensive clinical and regulatory history.
FDA regulatory position
| Regulatory issue |
Assessment |
| New molecular entity status |
No |
| FDA-approved product |
Yes |
| Current brand marketing |
No meaningful active brand presence |
| Generic substitution |
Available |
| Controlled substance |
Schedule IV |
| Pediatric positioning |
Limited; benzodiazepine safety concerns restrict use |
| Abuse-deterrent designation |
No |
| Biosimilar pathway |
Not applicable |
The Orange Book is relevant mainly to the historical approval and generic-equivalence framework. Niravam’s commercial exposure is limited because generic alprazolam products compete directly with the same active ingredient and therapeutic indications.[2]
Are there active clinical trials for Niravam?
No active Niravam-specific clinical development program is established as a commercial investment opportunity. The product’s clinical evidence is based on alprazolam development and the regulatory review supporting the orally disintegrating formulation.
ClinicalTrials.gov contains studies involving alprazolam for anxiety, panic disorder, sedation and other research purposes. Those studies should not be treated as clinical development for Niravam unless they specifically identify Niravam as the investigational product or sponsor asset.[3]
Clinical-trial assessment
| Trial category |
Niravam relevance |
| New indication trials |
No active branded program identified |
| Phase 2 or Phase 3 development |
No current Niravam program |
| Pediatric expansion |
No commercial program identified |
| Abuse-deterrence studies |
No approved Niravam program |
| Combination therapy studies |
Not evidence of Niravam development |
| Generic bioequivalence studies |
May support generic products, not brand revitalization |
The absence of a branded trial program is consistent with the product’s age, generic competition and the unfavorable risk-benefit profile of long-term benzodiazepine use.
When did Niravam lose market exclusivity?
Niravam’s meaningful exclusivity period ended after generic alprazolam products entered the market. The active ingredient was already an established generic molecule, so the commercial protection for Niravam was tied to the branded formulation and applicable formulation patents, not to composition-of-matter protection for alprazolam.
The product no longer has an effective commercial exclusivity position. Generic alprazolam tablets and ODT products can compete on price, reimbursement and pharmacy substitution.
Exclusivity timeline
| Period |
Event |
| Pre-2003 |
Alprazolam already established as a marketed benzodiazepine |
| 2003 |
FDA approval of Niravam |
| Post-approval period |
Brand competes through orally disintegrating delivery and trademark |
| Generic-entry period |
Generic alprazolam products reduce brand pricing power |
| Current status |
Brand is commercially discontinued; generic market remains active |
Niravam’s approval did not create durable molecular exclusivity. Its differentiator was the dosage form, which is generally more vulnerable to generic competition than a novel active ingredient protected by a long patent term.
What patents protect Niravam?
Niravam was protected primarily through formulation, dosage-form and regulatory exclusivity mechanisms rather than a surviving composition-of-matter patent on alprazolam.
The relevant intellectual-property categories were:
- Oral-disintegration technology
- Tablet composition
- Taste masking and excipient systems
- Manufacturing processes
- Trademark rights in the Niravam name
- Any applicable formulation patent or patent-term adjustment
The exact patent portfolio should be reviewed through historical FDA Orange Book records, USPTO prosecution files and assignment databases. The commercial conclusion is clear: any historical formulation protection did not prevent generic alprazolam competition from becoming the dominant market structure.
How strong is the Niravam patent estate?
The estate is weak as a current commercial barrier for four reasons:
- Alprazolam is an old, well-established active ingredient.
- Conventional alprazolam tablets provide a low-cost therapeutic substitute.
- Oral disintegration is a dosage-form differentiation rather than a new pharmacologic mechanism.
- The brand is no longer positioned as an actively defended commercial franchise.
A formulation patent can delay direct ODT competition, but it does not prevent substitution by conventional tablets where clinical circumstances permit. The protection is therefore narrower than the protection available to a novel drug, long-acting injectable or biologic.
What formulations are protected by Niravam-related intellectual property?
The relevant formulation concept is an orally disintegrating alprazolam tablet. Such products generally rely on rapidly dissolving excipients, compression technology and palatability controls.
Potentially protectable formulation elements include:
- Alprazolam particle size
- Disintegrant selection
- Compression force
- Tablet porosity
- Flavoring agents
- Taste-masking agents
- Moisture control
- Packaging that protects tablet integrity
These features may support formulation patents or know-how, but they do not necessarily prevent an alternative manufacturer from developing a different ODT formulation or marketing conventional alprazolam tablets.
Which companies compete with Niravam?
Niravam competes in two separate markets: the branded alprazolam market and the broader anti-anxiety market.
Generic alprazolam competitors
Generic competition has historically included products marketed by major U.S. generic manufacturers such as:
- Teva Pharmaceuticals
- Actavis, now part of Teva
- Mylan, now part of Viatris
- Sandoz
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals
- Rising Pharmaceuticals
- Other FDA-approved generic manufacturers
The exact active supplier set changes with procurement contracts, shortages, manufacturing decisions and wholesaler sourcing.
Therapeutic competitors
Niravam also competes with:
- Generic alprazolam conventional tablets
- Lorazepam
- Clonazepam
- Diazepam
- Buspirone
- Selective serotonin reuptake inhibitors
- Serotonin-norepinephrine reuptake inhibitors
- Cognitive behavioral therapy and other non-drug treatments
For acute anxiety or panic symptoms, other benzodiazepines can substitute clinically. For long-term anxiety management, non-benzodiazepine therapies face fewer dependence-related restrictions and are favored in many treatment guidelines.
What is the market size and revenue outlook for Niravam?
Niravam itself has negligible current branded revenue potential because the brand is discontinued and generic alprazolam dominates the category. Public revenue disclosure for Niravam is not a reliable basis for a standalone forecast.
The addressable market should instead be divided into three segments:
| Segment |
Current outlook |
| Niravam branded product |
Negligible |
| Generic alprazolam tablets |
Mature, price-competitive market |
| Generic alprazolam ODT |
Small niche with limited differentiation |
| Broader anxiety and panic treatment |
Large but fragmented across drug classes |
Five-year commercial projection
| Scenario |
Niravam brand |
Alprazolam ODT category |
Commercial interpretation |
| Base case |
No material recovery |
Low-single-digit growth or flat |
Generic pricing and limited differentiation |
| Upside case |
Limited relaunch value |
Modest growth |
Requires a new owner, supply restoration and differentiated packaging or access |
| Downside case |
Remains inactive |
Decline in benzodiazepine use |
Safety concerns and movement toward non-benzodiazepine therapy |
The brand’s relaunch economics are unfavorable. A relaunch would require manufacturing reactivation, controlled-substance compliance, distribution, pharmacovigilance, brand investment and payer access. These costs would be difficult to recover without premium pricing or a meaningful delivery advantage.
What generic entry risks exist for Niravam?
Generic entry risk is effectively realized rather than prospective. The primary competitive risks are:
- Direct generic alprazolam ODT substitution
- Substitution by conventional alprazolam tablets
- Lower-cost competing benzodiazepines
- Payer preference for generic products
- Increasing prescribing restrictions for benzodiazepines
- Reduced use in chronic anxiety because of dependence and withdrawal concerns
A future branded relaunch would face a low barrier to substitution. Even if the brand restored supply, prescribers and pharmacies would have limited economic reasons to choose it unless the ODT format solved a specific adherence or administration problem.
What patent litigation affects Niravam?
No major active patent-litigation opportunity is associated with Niravam as a discontinued product. Historical litigation, if any, would have centered on generic entry, formulation patents or regulatory certifications. It would not materially change the current market analysis unless a surviving patent or enforceable settlement restricted generic supply.
Paragraph IV challenge exposure
Generic applicants for a listed drug may challenge relevant patents through a Paragraph IV certification. For Niravam, the commercial impact of any historical Paragraph IV dispute has largely been overtaken by:
- Patent expiration or loss of practical enforceability
- Generic availability
- Brand discontinuation
- The availability of alternative alprazolam dosage forms
There is no current branded franchise whose value depends on defending a remaining Niravam patent blockade.
Are there licensing deals involving Niravam?
No material current licensing transaction has established Niravam as a strategic growth asset. The product originated with Schwarz Pharma and became associated with UCB following corporate changes. Any historical rights transfer would have limited present value because the brand is no longer a major commercial product.
A potential acquisition or license would have strategic logic only if it included:
- A reactivated manufacturing source
- Current regulatory rights
- Valid trademark rights
- Transferable formulation know-how
- A differentiated ODT platform
- A commercial plan addressing controlled-substance distribution
Without those assets, a Niravam transaction would be a low-value legacy-product deal rather than a conventional growth licensing opportunity.
How does Niravam compare with generic alprazolam tablets?
| Factor |
Niravam |
Generic alprazolam tablet |
| Active ingredient |
Alprazolam |
Alprazolam |
| Administration |
Dissolves in mouth |
Swallowed with water |
| Brand status |
Discontinued |
Widely available |
| Price position |
Historically premium |
Low-cost |
| Patent leverage |
Limited and historical |
Generic approval pathway |
| Payer preference |
Weak |
Strong |
| Clinical advantage |
Convenience in selected patients |
Familiar and inexpensive |
| Commercial outlook |
Minimal |
Mature, ongoing demand |
Niravam’s only meaningful product distinction is administration convenience. That advantage is insufficient to offset the price and availability advantages of generic alprazolam tablets for most patients.
What is the generic launch outlook for Niravam?
A new generic manufacturer would likely pursue one of two routes:
- Develop an alprazolam ODT equivalent, requiring formulation development and bioequivalence support.
- Market conventional alprazolam tablets, competing in the larger and more established segment.
The second route has a broader market but heavier generic competition. The first route has more dosage-form differentiation but a smaller market and potentially greater formulation complexity.
A branded Niravam relaunch would face a more difficult launch environment than a new generic because it would need to establish a price premium in a category where the active ingredient is widely available.
Does Niravam have biosimilar risk?
No. Biosimilar risk does not apply because Niravam is a small-molecule alprazolam product, not a biologic. Its competitive risk comes from generic-drug substitution, formulation alternatives and therapeutic substitutes.
What is the geographic market outlook?
Niravam’s commercial relevance is primarily U.S.-based because the brand name and FDA approval are U.S. regulatory assets. Geographic expansion would require separate approvals, controlled-substance compliance and local market access.
| Region |
Outlook |
| United States |
Brand discontinued; generic alprazolam remains available |
| European Union |
Local alprazolam products and national regulatory frameworks dominate |
| Canada |
Separate approval and controlled-substance requirements |
| Asia-Pacific |
Generic benzodiazepine markets vary by country |
| Emerging markets |
Price-sensitive, with local generic competition |
The U.S. market offers the clearest historical regulatory record, but not a compelling brand-relaunch case.
What manufacturing and IP barriers remain?
Manufacturing barriers are moderate. Alprazolam is a mature small molecule, but an ODT product requires appropriate control of:
- Dose uniformity
- Tablet friability
- Disintegration time
- Moisture sensitivity
- Taste
- Stability
- Controlled-substance inventory and distribution
The main barrier is commercial rather than scientific. A manufacturer can develop an ODT platform, but the market may not support the added cost of a differentiated product.
Key Takeaways
- Niravam is the discontinued U.S. brand for alprazolam orally disintegrating tablets.
- The product was FDA-approved for anxiety disorder and panic disorder.
- No active Niravam-specific clinical development program is commercially material.
- Alprazolam’s underlying molecule is generic and does not provide current branded exclusivity.
- Formulation and dosage-form protection were the principal historical IP categories.
- Generic alprazolam tablets are the primary competitive threat and have already displaced the brand.
- Biosimilar risk does not apply.
- Niravam has negligible current branded revenue potential.
- A relaunch would face low switching costs, generic substitution and benzodiazepine safety concerns.
- The alprazolam ODT market is a small niche within a mature generic category.
FAQs
Is Niravam still available by prescription?
Niravam is not an actively marketed branded product in the United States. Generic alprazolam products remain available, subject to prescription and controlled-substance requirements.
Is Niravam the same as Xanax?
Yes. Both contain alprazolam. Niravam was an orally disintegrating formulation, while Xanax has historically been marketed primarily in conventional tablet and extended-release forms.
Can generic alprazolam replace Niravam?
A pharmacist may substitute an FDA-approved generic equivalent where an equivalent alprazolam ODT is available and state substitution rules permit it. Conventional alprazolam tablets are therapeutically related but do not have the same dosage form.
Does alprazolam have a long-term growth market?
The molecule has continuing demand for short-term anxiety and panic treatment, but long-term growth is constrained by dependence, withdrawal, misuse, overdose and opioid co-prescription concerns.
Would a Niravam relaunch be commercially attractive?
The relaunch case is weak. A sponsor would need a supply, regulatory, manufacturing and market-access strategy capable of generating a premium over widely available generic alprazolam products.
References
- U.S. Food and Drug Administration. (2023). Niravam (alprazolam) orally disintegrating tablets prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- National Library of Medicine. (2024). ClinicalTrials.gov: Search results for alprazolam and anxiety disorders.
- U.S. Drug Enforcement Administration. (2024). Drug scheduling and controlled substances information.
